Genmab — Juli 2017
-
Fra Nordea: We expect Darzalex sales to accelerate in H2 2017, fuelled by increased penetration in second-line MM, the label expansion with Pomalyst in the US, and additional launches in Europe with a much broader second-line label. The traction in the second-line setting is likely to be the main driver for a further acceleration in sales.
-
CLL cells opsonized with hexamerization-enhanced CD20 mAb Hx-7D8 are rapidly killed by CDC in the complete absence of C9, suggesting that assembly of small C5b-8 pores is sufficient for CDC. This finding supports the potential for future use of hexamer-formation enhanced mAbs in cancer immunotherapy.
-
Det kynne tyde på at hexa-cd20 kunne gøre rituximab/imbruvica rangen stridig...
-
...men det er jo altsammen ligegyldigt, da Carnegie har fortalt os, at GEN kan glemme alt om omsætning uden for Dara
-
arrzhex...
-
Vedr. besøg i Genmabs nye lokaliteter i Holland kan det først blive i starten af 2018. Indflytning forventes nemlig først sidst i 2017.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind